Epidermal growth factor receptor (EGFR) mutation is currently the most common target; EGFR mutations were more common in Chinese patients than in American patients (27), which might result in our patients that accepted immunotherapy of non-squamous NSCLC (11/55, 20%) is less than of squamous cell carcinoma (44/55, 80%). This evidence concerns the gene EGFR and squamous cell carcinoma.